A new wave of personalized gene‑editing ventures has emerged to exploit evolving regulatory pathways for bespoke therapies. Aurora Therapeutics, backed by Menlo Ventures and co‑founded by CRISPR pioneers, aims to scale bespoke CRISPR treatments for rare diseases such as PKU by grouping variant edits under unified development paths. Founders and advisors stress recent FDA guidance on 'plausible mechanism' routes as enabling for personalized programs.